Lun - Ven 8:00 - 17:00

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

Education environnementale
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

Ecotourisme
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

Développement Communautaire
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

ODDB ONG

Sildenafil Citrate 150 Mg - Sextreme Red Force

Sildenafil > sildenafil citrate 150 mg red pill


The results indicate that there is no significant difference in mean change from baseline on 6MWD observed between sildenafil 20 mg plus bosentan and bosentan alone.Study A1481324 (NCT02060487) - Study to Assess the Effects of Sildenafil on Mortality in Adults with PAHA study to assess the effects of multiple doses of sildenafil on mortality in adults with PAH was conducted following the observation of a higher risk of mortality in pediatric patients taking a high dose of sildenafil TID, based on body weight, compared to those taking a lower dose of sildenafil in the long-term extension of the pediatric clinical trial.The study was a randomized, double-blind, parallel-group study in 385 adults with PAH. Patients were randomly assigned 1:1:1 to one of three treatment groups (5, 20, and 80 mg TID). Most patients were PAH treatment naïve (83%). For most patients the etiology of PAH was idiopathic (72%). The most common WHO Functional Class was Class III (58% of patients). Treatment groups were well balanced with respect to baseline demographics of strata history of PAH treatment and etiology of PAH, as well as the WHO Functional Class categories.The primary objective of the study was to compare sildenafil 80 mg TID versus 5 mg TID for mortality, with success defined by ruling out twice the mortality at 80 mg.The key secondary efficacy endpoint was time to first event of clinical worsening, defined as a composite endpoint of all-cause mortality, hospitalization for worsening PAH or disease progression.

In case of emergency/overdose

On treatment deaths: Any death within 7 days of last dose was regarded as “On treatment”, thus might include deaths occurred after discontinuation from study treatment.b. Hazard ratio estimates from the proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.Kaplan-Meier estimates of survival at 3 years were 66%, 79%, and 85% in the 5-, 20-, and 80- mg TID dose groups, respectively.Clinical WorseningSildenafil 80 mg was also superior to 5 mg for time to first event of clinical worsening with HR (99.7% CI) = 0.44 (0.22, 0.89).Table 7. Hazard Ratios for Time to First Event of Clinical Worsening – Intent To Treat PopulationNote: Sildenafil 5 mg is not an approved dosage.Abbreviations: 6MWD = 6-minute walk distance; CI = confidence interval; PAH = pulmonary arterial hypertension.a. Clinical worsening events were defined as reduction from baseline in the 6MWD test by at least 15% and worsening functional class from baseline, sildenafil 100 mg tab both confirmed by a second test/evaluation within 2 weeks.b. Count of cases of disease progression as the first event of clinical worsening.c.

How long does Cenforce 150mg last?

Count of non-elective hospital stays for worsening PAH as the first event of clinical worsening.d. Count of deaths as the first event of clinical worsening.e. Hazard ratio estimates from the proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH. P-value from the Wald test.6MWD at Months 6 and 12At baseline, the median of 6MWD for the intent-to-treat (ITT) population was 332 to 352 m. At Month 6, the median change from baseline was highest for sildenafil 80 mg TID with 28 m compared to 18 m and 19 m for sildenafil 5 mg TID and sildenafil 20 mg TID groups, respectively.The same was seen at Month 12, the median change from baseline for sildenafil 80 mg TID group was 33 m compared to 17 m for sildenafil 5 mg TID and 31 m in sildenafil 20 mg TID groups.Overall, the safety data for sildenafil 20 mg TID and for the higher sildenafil 80 mg TID dose were consistent with the established safety profile of sildenafil in previous adult PAH studies [see Adverse Reactions (6.1)].Pediatric use information is approved for Viatris Specialty LLC's, REVATIO (sildenafil) tablets. An additional secondary endpoint was 6MWD at Months 6 and 12.Overall SurvivalAt the time of a planned interim analysis (50% deaths) it was identified that the primary efficacy objective of this protocol was met and therefore the study was stopped. Based on the primary efficacy endpoint (mortality), the non-inferiority of sildenafil 80 mg TID arm versus 5 mg TID arm was met using a 2-sided significance level of 0.003 for the interim analysis.

  • Sildenafil citrate may interact with other medications like alpha-blockers or protease inhibitors.
  • Inform your healthcare provider of all medications before using sildenafil.
  • Overdose can cause serious side effects such as vision changes or chest pain.

Primary comparison of the 80 mg TID group to the 5 mg TID group yielded the HR (99.7% CI) = 0.51 (0.22, 1.21); i.e., non-inferiority was established.Table 6. Hazard Ratios for Overall Survival, Assessed in the Proportional Hazards Model – Intent To Treat Populationa. On treatment deaths: Any death within 7 days of last dose was regarded as “On treatment”, thus might include deaths occurred after discontinuation from study treatment.b. Hazard ratio estimates from the proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH.Kaplan-Meier estimates of survival at 3 years were 66%, 79%, and 85% in the 5-, 20-, and 80- mg TID dose groups, respectively.Clinical WorseningSildenafil 80 mg was also superior to 5 mg for time to first event of clinical worsening with HR (99.7% CI) = 0.44 (0.22, 0.89).Table 7.

Condition Usage Recommendation Typical Dose Notes
Erectile Dysfunction 150 mg before sexual activity 150 mg as needed Take on an empty stomach for best effect
Pulmonary Hypertension Under medical supervision Custom dose Usually lower doses, different formulation
Off-label Use As prescribed by doctor Varies Not FDA approved for off-label uses

Hazard Ratios for Time to First Event of Clinical Worsening – Intent To Treat PopulationNote: Sildenafil 5 mg is not an approved dosage.Abbreviations: 6MWD = 6-minute walk distance; CI = confidence interval; PAH = pulmonary arterial hypertension.a. Clinical worsening events were defined as reduction from baseline in the 6MWD test by at least 15% and worsening functional class from baseline, sildenafil 100 mg tab both confirmed by a second test/evaluation within 2 weeks.b. Count of cases of disease progression as the first event of clinical worsening.c.

Product Dosage Quantity + Bonus Price
Viagra Generic50mg90 + 6 Pills107.37€ 102.26€
Viagra Generic25mg180 + 6 Pills154.93€ 147.55€
Kamagra100mg120 + 6 Pills330.74€ 314.99€
Kamagra Polo100mg84 + 4 Pills244.49€ 232.85€
Kamagra100mg20 Pills86.09€ 81.99€
Viagra Generic150mg30 + 2 Pills72.32€ 68.88€
Kamagra Polo100mg272 + 12 Pills622.94€ 593.28€
Viagra Generic200mg60 + 4 Pills125.19€ 119.23€
Viagra Generic25mg360 + 10 Pills213.68€ 203.50€
Viagra Generic50mg60 + 4 Pills83.93€ 79.93€
Kamagra Soft Tabs100mg84 + 4 Pills233.05€ 221.95€
Viagra Generic25mg30 + 4 Pills47.97€ 45.69€
Kamagra Polo100mg120 + 6 Pills327.15€ 311.57€
Kamagra Oral Jelly100mg220 + 18 Sachets662.24€ 630.70€
Viagra Generic100mg270 + 10 Pills270.47€ 257.59€
Viagra Generic25mg270 + 8 Pills184.26€ 175.49€
Viagra Generic150mg60 + 4 Pills111.25€ 105.95€

Count of non-elective hospital stays for worsening PAH as the first event of clinical worsening.d. Count of deaths as the first event of clinical worsening.e.

Fildena Super Active Tablets

PACES-1 (NCT00159861) - Sildenafil citrate Co-Administered with Epoprostenol A randomized, double-blind, placebo-controlled study (PACES-1) was conducted in 267 patients with PAH who were taking stable doses of intravenous epoprostenol. Patients were randomized to placebo or sildenafil citrate (in a fixed titration starting from 20 mg to 40 mg and then 80 mg, three times a day) and all patients continued intravenous epoprostenol therapy. At baseline patients had PPH (80%) or PAH secondary to CTD (20%);WHO Functional Class I (1%), II (26%), III (67%), or IV (6%); and the mean age was 48 years, 80% were female, and 79% were Caucasian. There was a statistically significant greater increase from baseline in 6-minute walk distance at Week 16 (primary endpoint) for the sildenafil citrate group compared with the placebo group. The mean change from baseline at Week 16 (last observation carried forward) pfizer sildenafil 100 was 30 meters for the sildenafil tablet group compared with 4 meters for the placebo group giving an adjusted treatment difference of 26 meters (95% CI: 10.8, 41.2) (p = 0.0009).

How can I buy cenforce 150 mg online from Iyrinhealth?

Patients on sildenafil citrate achieved a statistically significant reduction in mPAP compared to those on placebo. A mean placebo-corrected treatment effect of -3.9 mmHg was observed in favor of sildenafil tablet (95% CI: -5.7, -2.1) (p = 0.00003). Time to clinical worsening of PAH was defined as the time from randomization to the first occurrence of a clinical worsening event (death, lung transplantation, initiation of bosentan therapy, or clinical deterioration requiring a change in epoprostenol therapy). Kaplan- Meier plot of time to clinical worsening is presented in Figure 5. Kaplan-Meier Plot of Time (in Days) to Clinical Worsening of PAH in PACES-1 Improvements in WHO Functional Class for PAH were also demonstrated in patients on sildenafil tablet compared to placebo. Hazard ratio estimates from the proportional Hazards model, stratified by actual previous PAH treatment and etiology of PAH. P-value from the Wald test.6MWD at Months 6 and 12At baseline, the median of 6MWD for the intent-to-treat (ITT) population was 332 to 352 m.

  • Sildenafil is not an aphrodisiac and requires sexual arousal to be effective.
  • The 150 mg dose is generally prescribed when lower doses are ineffective.
  • It is important to follow doctor's guidance on usage to avoid health risks.

At Month 6, the median change from baseline was highest for sildenafil 80 mg TID with 28 m compared to 18 m and 19 m for sildenafil 5 mg TID and sildenafil 20 mg TID groups, respectively.The same was seen at Month 12, the median change from baseline for sildenafil 80 mg TID group was 33 m compared to 17 m for sildenafil 5 mg TID and 31 m in sildenafil 20 mg TID groups.Overall, the safety data for sildenafil 20 mg TID and for the higher sildenafil 80 mg TID dose were consistent with the established safety profile of sildenafil in previous adult PAH studies [see Adverse Reactions (6.1)].Pediatric use information is approved for Viatris Specialty LLC's, REVATIO (sildenafil) tablets. SUPER-1 (NCT00644605) - Sildenafil citrate Monotherapy [20 mg, 40 mg, and 80 mg Three Times a Day] A randomized, double-blind, placebo-controlled study of sildenafil citrate (SUPER-1) was conducted in 277 patients with PAH (defined as a mean pulmonary artery pressure≥25 mmHg at rest with a pulmonary capillary wedge pressure<15 mmHg). Patients with left ventricular ejection fraction less than 45% or left ventricular shortening fraction less than 0.2 also were not studied. Patients were randomized to receive placebo (n=70) or sildenafil tablet 20 mg (n = 69), 40 mg (n = 67) or 80 mg (n = 71) three times a day for a period of 12 weeks. The study population consisted of 25% men and 75% women with a mean age of 49 years (range: 18 to 81 years) and baseline 6-minute walk distance between 100 and 450 meters (mean 343).

Condition Contraindication Precautions
Use with nitrate medications Absolute contraindication Can cause severe hypotension
Heart disease Consult doctor before use Risk of cardiovascular events
Liver or kidney impairment Use with caution May require dose adjustments
Allergies to sildenafil or excipients Allergic reactions possible Discontinue if adverse effects occur

The primary efficacy endpoint was the change from baseline at Week sildenafil oral jelly 100mg lovegra 12 (at least 4 hours after the last dose) in the 6-minute walk distance. The improvement in walk distance was apparent after 4 weeks of treatment and was maintained at Week 8 and Week 12.

Recommended Dosage

More than twice as many sildenafil citrate-treated patients (36%) as placebo-treated patients (14%) showed an improvement in at least one functional New York Heart Association (NYHA) class for PAH. Study A1481243 (NCT00323297) – Sildenafil citrate Added to Bosentan Therapy – Lack of Effect on Exercise Capacity A randomized, double-blind, placebo-controlled study was conducted in 103 patients with PAH who were on bosentan therapy for a minimum of 3 months. The results indicate that there is no significant difference in mean change from baseline on 6MWD observed between sildenafil 20 mg plus bosentan and bosentan alone. Study A1481324 (NCT02060487) - Study to Assess the Effects of Sildenafil on Mortality in Adults with PAH A study to assess the effects of multiple doses of sildenafil on mortality in adults with PAH was conducted following the observation of a higher risk of mortality in pediatric patients taking a high dose of sildenafil TID, based on body weight, compared to those taking a lower dose of sildenafil in the long-term extension of the pediatric clinical trial. The study was a randomized, double-blind, parallel-group study in 385 adults with PAH.

Is free delivery available at Pharmabridge International?

Treatment groups were well balanced with respect to baseline demographics of strata history of PAH treatment and etiology of PAH, as well as the WHO Functional Class categories. The primary objective of the study was to compare sildenafil 80 mg TID versus 5 mg TID for mortality, with success defined by ruling out twice the mortality at 80 mg. Change from Baseline in 6-Minute Walk Distance (meters) at Weeks 4, 8, and 12 in SUPER-1: Mean (95% Confidence Interval) Figure 4 displays subgroup efficacy analyses in SUPER-1 for the change from baseline in 6-Minute Walk Distance at Week 12 including baseline walk distance, disease etiology, functional class, gender, age, and hemodynamic parameters.

Why source Cenforce 150 mg Tablet (Red Pill) from Oddway International

The results indicate that there is no significant difference in mean change from baseline on 6MWD observed between sildenafil 20 mg plus bosentan and bosentan alone.Study A1481324 (NCT02060487) - Study to Assess the Effects of Sildenafil on Mortality in Adults with PAHA study to assess the effects of multiple doses of sildenafil on mortality in adults with PAH was conducted following the observation of a higher risk of mortality in pediatric patients taking a high dose of sildenafil TID, based on body weight, compared to those taking a lower dose of sildenafil in the long-term extension of the pediatric clinical trial.The study was a randomized, double-blind, parallel-group study in 385 adults with PAH. Patients were randomly assigned 1:1:1 to one of three treatment groups (5, 20, and 80 mg TID). Most patients were PAH treatment naïve (83%). For most patients the etiology of PAH was idiopathic (72%). The most common WHO Functional Class was Class III (58% of patients).

Positive Outcomes:

Treatment groups were well balanced with respect to baseline demographics of strata history of PAH treatment and etiology of PAH, as well as the WHO Functional Class categories.The primary objective of the study was to compare sildenafil 80 mg TID versus 5 mg TID for mortality, with success defined by ruling out twice the mortality at 80 mg.The key secondary efficacy endpoint was time to first event of clinical worsening, defined as a composite endpoint of all-cause mortality, hospitalization for worsening PAH or disease progression. An additional secondary endpoint was 6MWD at Months 6 and 12.Overall SurvivalAt the time of a planned interim analysis (50% deaths) it was identified that the primary efficacy objective of this protocol was met and therefore the study was stopped. Based on the primary efficacy endpoint (mortality), the non-inferiority of sildenafil 80 mg TID arm versus 5 mg TID arm was met using a 2-sided significance level of 0.003 for the interim analysis. Primary comparison of the 80 mg TID group to the 5 mg TID group yielded the HR (99.7% CI) = 0.51 (0.22, 1.21); i.e., non-inferiority was established.Table 6. Hazard Ratios for Overall Survival, Assessed in the Proportional Hazards Model – Intent To Treat Populationa. Placebo-Corrected Change from Baseline in 6-Minute Walk Distance (meters) at Week 12 by Study Subpopulation in SUPER-1: Mean (95% Confidence Interval) Key: PAH = pulmonary arterial hypertension; CTD = connective tissue disease; PH = pulmonary hypertension; PAP = pulmonary arterial pressure; PVRI = pulmonary vascular resistance index; TID = three times daily. SUPER-2 (NCT00159887) Long-Term Treatment of PAH In a long-term follow-up of patients who were treated with sildenafil (n=277), K-M estimates of survival at 1, 2, and 3 years were 94%, 88% , and 79%, respectively. These uncontrolled observations do not allow comparison with a group not given sildenafil and cannot be used to determine the long term-effect of sildenafil on mortality.

Who Should and Should Not Consider Cenforce 150?

PACES-1 (NCT00159861) - Sildenafil citrate Co-Administered with Epoprostenol A randomized, double-blind, placebo-controlled study (PACES-1) was conducted in 267 patients with PAH who were taking stable doses of intravenous epoprostenol.

Authenticity Checklist for Safe Purchasing

SUPER-1 (NCT00644605) - Sildenafil citrate Monotherapy [20 mg, 40 mg, and 80 mg Three Times a Day] A randomized, double-blind, placebo-controlled study of sildenafil citrate (SUPER-1) was conducted in 277 patients with PAH (defined as a mean pulmonary artery pressure≥25 mmHg at rest with a pulmonary capillary wedge pressure<15 mmHg). Patients with left ventricular ejection fraction less than 45% or left ventricular shortening fraction less than 0.2 also were not studied. Patients were randomized to receive placebo (n=70) or sildenafil tablet 20 mg (n = 69), 40 mg (n = 67) or 80 mg (n = 71) three times a day for a period of 12 weeks. The study population consisted of 25% men and 75% women with a mean age of 49 years (range: 18 to 81 years) and baseline 6-minute walk distance between 100 and 450 meters (mean 343). The primary efficacy endpoint was the change from baseline at Week sildenafil oral jelly 100mg lovegra 12 (at least 4 hours after the last dose) in the 6-minute walk distance.

Sildenafil may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

The improvement in walk distance was apparent after 4 weeks of treatment and was maintained at Week 8 and Week 12. Change from Baseline in 6-Minute Walk Distance (meters) at Weeks 4, 8, and 12 in SUPER-1: Mean (95% Confidence Interval) Figure 4 displays subgroup efficacy analyses in SUPER-1 for the change from baseline in 6-Minute Walk Distance at Week 12 including baseline walk distance, disease etiology, functional class, gender, age, and hemodynamic parameters. Placebo-Corrected Change from Baseline in 6-Minute Walk Distance (meters) at Week 12 by Study Subpopulation in SUPER-1: Mean (95% Confidence Interval) Key: PAH = pulmonary arterial hypertension; CTD = connective tissue disease; PH = pulmonary hypertension; PAP = pulmonary arterial pressure; PVRI = pulmonary vascular resistance index; TID = three times daily. SUPER-2 (NCT00159887) Long-Term Treatment of PAH In a long-term follow-up of patients who were treated with sildenafil (n=277), K-M estimates of survival at 1, 2, and 3 years were 94%, 88% , and 79%, respectively. These uncontrolled observations do not allow comparison with a group not given sildenafil and cannot be used to determine the long term-effect of sildenafil on mortality. Patients were randomized to placebo or sildenafil citrate (in a fixed titration starting from 20 mg to 40 mg and then 80 mg, three times a day) and all patients continued intravenous epoprostenol therapy. At baseline patients had PPH (80%) or PAH secondary to CTD (20%);WHO Functional Class I (1%), II (26%), III (67%), or IV (6%); and the mean age was 48 years, 80% were female, and 79% were Caucasian. There was a statistically significant greater increase from baseline in 6-minute walk distance at Week 16 (primary endpoint) for the sildenafil citrate group compared with the placebo group. The mean change from baseline at Week 16 (last observation carried forward) pfizer sildenafil 100 was 30 meters for the sildenafil tablet group compared with 4 meters for the placebo group giving an adjusted treatment difference of 26 meters (95% CI: 10.8, 41.2) (p = 0.0009). Patients on sildenafil citrate achieved a statistically significant reduction in mPAP compared to those on placebo. A mean placebo-corrected treatment effect of -3.9 mmHg was observed in favor of sildenafil tablet (95% CI: -5.7, -2.1) (p = 0.00003).

  • Sildenafil citrate metabolism can be affected by liver or kidney impairment.
  • Dosage adjustments might be needed in such cases.
  • Always report any pre-existing health conditions to your doctor.

Time to clinical worsening of PAH was defined as the time from randomization to the first occurrence of a clinical worsening event (death, lung transplantation, initiation of bosentan therapy, or clinical deterioration requiring a change in epoprostenol therapy). Kaplan- Meier plot of time to clinical worsening is presented in Figure 5. Kaplan-Meier Plot of Time (in Days) to Clinical Worsening of PAH in PACES-1 Improvements in WHO Functional Class for PAH were also demonstrated in patients on sildenafil tablet compared to placebo.

Aspect Details Recommendations
Storage Temperature 15°C to 30°C Keep in a cool, dry place
Light exposure Protect from light Store in opaque container
Humidity Avoid high humidity Keep away from bathrooms or humid areas
Shelf Life 2-3 years Check expiry date before use

More than twice as many sildenafil citrate-treated patients (36%) as placebo-treated patients (14%) showed an improvement in at least one functional New York Heart Association (NYHA) class for PAH. Study A1481243 (NCT00323297) – Sildenafil citrate Added to Bosentan Therapy – Lack of Effect on Exercise Capacity A randomized, double-blind, placebo-controlled study was conducted in 103 patients with PAH who were on bosentan therapy for a minimum of 3 months. The results indicate that there is no significant difference in mean change from baseline on 6MWD observed between sildenafil 20 mg plus bosentan and bosentan alone. Study A1481324 (NCT02060487) - Study to Assess the Effects of Sildenafil on Mortality in Adults with PAH A study to assess the effects of multiple doses of sildenafil on mortality in adults with PAH was conducted following the observation of a higher risk of mortality in pediatric patients taking a high dose of sildenafil TID, based on body weight, compared to those taking a lower dose of sildenafil in the long-term extension of the pediatric clinical trial. The study was a randomized, double-blind, parallel-group study in 385 adults with PAH.

  • Sildenafil citrate 150 mg should not be used by individuals under 18 years old.
  • Pregnant or breastfeeding women should consult a doctor before exposure.
  • The drug is intended solely for male erectile dysfunction.

Treatment groups were well balanced with respect to baseline demographics of strata history of PAH treatment and etiology of PAH, as well as the WHO Functional Class categories. The primary objective of the study was to compare sildenafil 80 mg TID versus 5 mg TID for mortality, with success defined by ruling out twice the mortality at 80 mg.

 Singes à ventre roux

10+

Années d'expérience

ODDB ONG

Domaines d'interventions

Les objectifs que
nous poursuivons

Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

En savoir plus
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

En savoir plus
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

En savoir plus
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

En savoir plus
ODDB ONG

Nos Projets

ODDB-ONG agit pour l'environnement et le mieux-être des communautés locales.

ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Merci de soutenir nos projets

Votre don nous permet d’agir, merci !

ODDB ONG

Question à nous poser

Une question d'ordre général ?

La biodiversité fait référence à la variété et à la diversité de la vie sur Terre, y compris toutes les espèces d'animaux, de plantes, de micro-organismes et les écosystèmes dans lesquels ils vivent. Cela englobe la richesse génétique au sein des espèces, la diversité des espèces elles-mêmes et la variété des habitats naturels. En résumé, la biodiversité représente la variété de la vie et des écosystèmes qui rendent notre planète unique et fonctionnelle.

Pour poursuivre nos actions pour la planète et en engager de nouvelles, nous sollicitons le soutien de tous. Chaque contribution est importante. Partagez nos campagnes, faites un don, devenez bénévole pour ODDB ONG et aidez-nous à préserver la nature.

Le logo du ODDB ONG est une marque internationale déposée et soumise au droit d'auteur. Toute utilisation ou reproduction est strictement interdite sans autorisation. Si vous souhaitez utiliser le logo dans le cadre d'un partenariat, veuillez écrire à l'adresse suivante. Pour toute autre utilisation, veuillez contacter l'adresse suivante.

Pour toute demande de stage, veuillez consulter régulièrement notre page dédiée au recrutement.

Pour commencer, il est essentiel d'adopter de bonnes habitudes quotidiennes : privilégier une alimentation équilibrée avec moins de protéines animales et favorisant les circuits courts, opter pour des modes de transport durables tels que les transports en commun ou le vélo, améliorer votre efficacité énergétique et votre utilisation numérique, et réduire la production de déchets. Toutes ces pratiques sont détaillées dans la section " Agir au quotidien".

Un accusé de réception vous est envoyé par mail pour vous confirmer la réception de votre dossier de candidature.

Les conséquences de la crise écologique sont manifestes : une agriculture en déclin, des plans d'eau épuisés, un accès difficile à l'eau douce et des forêts en difficulté pour préserver la biodiversité. Notre enjeu environnemental majeur est clair : l'urgence d'agir. Cette nécessité ne concerne plus seulement les générations futures, mais également la population actuelle, qui subit déjà les perturbations profondes engendrées par la crise écologique.
singe a ventre rouge
ODDB ONG

Galerie

Nos Actions En Image

Dendroaspis jamesoni
ODDB ONG
Dendroaspis jamesoni
Benin Potto (Perodicticus potto juju)
ODDB ONG
Benin Potto (Perodicticus potto juju)
Singe tantale (Chlorocebus aethiops tantalus)
ODDB ONG
Singe tantale (Chlorocebus aethiops tantalus)
Female Sitatunga with offspring (Tragelaphus spekii)
ODDB ONG
Female Sitatunga with offspring (Tragelaphus spekii)
Cercopithecus aethiops tantalus
ODDB ONG
Cercopithecus aethiops tantalus
Coucal noir (Centropus senegalensis)
ODDB ONG
Coucal noir (Centropus senegalensis)
Cercopithecus erythrogaster
ODDB ONG
Cercopithecus erythrogaster
Female sitatunga (Tragelaphus spekii)
ODDB ONG
Female sitatunga (Tragelaphus spekii)
Gnanhouizoun community forest, Ouémé valley
ODDB ONG
Gnanhouizoun community forest, Ouémé valley
chouette
ODDB ONG
chouette
Héron cendré (Ardea cinerea)
ODDB ONG
Héron cendré (Ardea cinerea)
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
ODDB ONG
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
ODDB ONG
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
Gnanhouizounmè au couché de soleil
ODDB ONG
Gnanhouizounmè au couché de soleil
Chamaeleo necasi
ODDB ONG
Chamaeleo necasi
Aigrette
ODDB ONG
Aigrette

Nos Statistiques

ODDB en chiffres

10+

10+

Années d'expérience

79

79Ha

de superficies reboisées

14K+

14K+

personnes sensibilisées

320

320

personnes autonomisées

151

151

Stagiaires et bénévoles formés pour suivi de la biodiversité

ODDB ONG

Nos Actualités

Actualités

Nos  Partenaires

Partenaires Techniques

little green guards Chester Zoo Institut des Tortues d'Afrique Conservatoire pour la Protection des Primates National Geographic

Partenaires Financiers

Primate Society of Great Britain SUCO INTERNATIONAL BENIN UP2GREEN The Rufford Foundation IKI